Lilly kicks off 2020’s predicted biopharma M&A boom with $1.1B Dermira deal

10th January 2020 Uncategorised 0

Eli Lilly is picking up Dermira for $1.1 billion, or $18.75 a share, more than double the value at which it was trading a month ago. Analysts expected the company to pursue oncology assets, but it’s still a smart deal, some say, because it brings Lilly both a marketed drug and a phase 3 asset in the hot area of atopic dermatitis.

More: Lilly kicks off 2020’s predicted biopharma M&A boom with .1B Dermira deal
Source: fierce